NCT06704581View on ClinicalTrials.gov

A Study of BGM0504 Injection in Participants with Obesity or Overweight

PHASE3RecruitingINTERVENTIONAL
Enrollment

620

Participants

Timeline

Start Date

October 28, 2024

Primary Completion Date

November 27, 2025

Study Completion Date

March 27, 2026

Conditions
Overweight or Obesity
Interventions
DRUG

5 mg BGM0504 injection

5mg BGM0504 injection administered subcutaneously (SC) once a week.

DRUG

10 mg BGM0504 injection administered subcutaneously (SC) once a week

10mg BGM0504 injection administered subcutaneously (SC) once a week.

DRUG

15 mg BGM0504 injection

15mg BGM0504 injection administered subcutaneously (SC) once a week.

DRUG

BGM0504 placebo

BGM0504 placebo administered SC once a week.

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.

INDUSTRY